Literature DB >> 23537056

Hepatocellular carcinoma as extracolonic manifestation of Lynch syndrome indicates SEC63 as potential target gene in hepatocarcinogenesis.

Markus Casper1, Susanne N Weber, Matthias Kloor, Roman Müllenbach, Rainer Grobholz, Frank Lammert, Vincent Zimmer.   

Abstract

OBJECTIVE: Lynch syndrome is a cancer predisposition syndrome caused by germline mutations in DNA mismatch repair (MMR) genes with microsatellite instability (MSI) as its molecular hallmark. Hepatocellular carcinoma (HCC) has not been considered part of the tumor spectrum. The aim was to provide a detailed molecular characterization of an HCC associated with Lynch Syndrome (Muir-Torre variant).
MATERIALS AND METHODS: HCC samples were analyzed for MSI, MMR protein expression and coding microsatellite instability (cMSI). Since cMSI also affected SEC63 coding for an endoplasmic reticulum membrane protein with implications for intracellular protein translocation, its impact on hepatocyte growth control was assessed in an established short-term model. Recombinant inbred mouse lines (BXD) showing different basal SEC63 expression levels were treated with the chemocarcinogen diethylnitrosamine (DEN) intraperitoneally. Proliferation and apoptosis of hepatocytes were determined after 48 h using Ki67 and TUNEL assays.
RESULTS: The HCC was high-grade microsatellite unstable with loss of MSH2 expression. cMSI was detected in four genes (ASTE1, SEC63, TAF1B, TGFBR2). However, only TGFBR2 is known to be involved in hepatocarcinogenesis. When investigating the impact of SEC63 expression on hepatocyte growth control in the murine model, low hepatic expression correlated significantly (p < 0.05) with a decrease in apoptosis and increased proliferative activity.
CONCLUSIONS: For the first time, an HCC with characteristic molecular features of association with Lynch syndrome is described. The pro-carcinogenic growth behavior of hepatocytes with low SEC63 expression in the murine model indicates a potential role for SEC63 in hepatocarcinogenesis in general, but this needs further functional validation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537056     DOI: 10.3109/00365521.2012.752030

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Aberrant expression of Sec61α in esophageal cancers.

Authors:  Kai Bachmann; Maximillian Bockhorn; Oliver Mann; Florian Gebauer; Marco Blessmann; Jakob Robert Izbicki; Katharina Grupp
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-13       Impact factor: 4.553

Review 2.  Is Nucleoredoxin a Master Regulator of Cellular Redox Homeostasis? Its Implication in Different Pathologies.

Authors:  Osiris Germán Idelfonso-García; Brisa Rodope Alarcón-Sánchez; Verónica Rocío Vásquez-Garzón; Rafael Baltiérrez-Hoyos; Saúl Villa-Treviño; Pablo Muriel; Héctor Serrano; Julio Isael Pérez-Carreón; Jaime Arellanes-Robledo
Journal:  Antioxidants (Basel)       Date:  2022-03-30

3.  SEC61G plays an oncogenic role in hepatocellular carcinoma cells.

Authors:  Huijie Gao; Weibo Niu; Zhaobin He; Chao Gao; Cheng Peng; Jun Niu
Journal:  Cell Cycle       Date:  2020-11-10       Impact factor: 4.534

Review 4.  Complexity and Specificity of Sec61-Channelopathies: Human Diseases Affecting Gating of the Sec61 Complex.

Authors:  Mark Sicking; Sven Lang; Florian Bochen; Andreas Roos; Joost P H Drenth; Muhammad Zakaria; Richard Zimmermann; Maximilian Linxweiler
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

5.  Differential expression and diagnostic significance of P53, MutS homologs 2, tropomyosin-4 in alpha-fetoprotein-negative hepatocellular carcinoma.

Authors:  Xuyang Gong; Ailong Huang
Journal:  J Clin Lab Anal       Date:  2020-05-03       Impact factor: 2.352

6.  Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report.

Authors:  Yu Feng; Yufeng Cao; Mingming Yuan; Rongrong Chen; Xue Ji; Xingsheng Hu
Journal:  Oncol Lett       Date:  2019-09-23       Impact factor: 2.967

7.  Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.

Authors:  Qunhao Zheng; Zhiping Wang; Mengyan Zhang; Yilin Yu; Rui Chen; Tianzhu Lu; Lingyun Liu; Jiayu Ma; Tianxiu Liu; Hongying Zheng; Hui Li; Jiancheng Li
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

8.  Pyroptosis-Related Risk Signature Exhibits Distinct Prognostic, Immune, and Therapeutic Landscapes in Hepatocellular Carcinoma.

Authors:  Yidi Zhao; Qingya Song; Fangshi Xu; Yang Zhou; Xiaoli Zuo; Zhengliang Zhang
Journal:  Front Genet       Date:  2022-03-09       Impact factor: 4.599

9.  A novel DNA damage response mediated by DNA mismatch repair in Caenorhabditis elegans: induction of programmed autophagic cell death in non-dividing cells.

Authors:  Takahito Moriwaki; Yuichi Kato; Chihiro Nakamura; Satoru Ishikawa; Qiu-Mei Zhang-Akiyama
Journal:  Genes Cancer       Date:  2015-07

Review 10.  Let's talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine.

Authors:  Maximilian Linxweiler; Bernhard Schick; Richard Zimmermann
Journal:  Signal Transduct Target Ther       Date:  2017-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.